However, PSA has some weaknesses as a biomarker, where it is also increased in benign prostatic hyperplasia, its expression levels can be similar in indolent and aggressive prostate cancer and it often fails to indicate patient response to a given treatment accurately. The gene discussed is KLK3; the disease is benign prostatic hyperplasia.